<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PI</journal-id><journal-title-group><journal-title>Pharmacy Information</journal-title></journal-title-group><issn pub-type="epub">2160-441X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/PI.2019.83017</article-id><article-id pub-id-type="publisher-id">PI-30513</article-id><article-categories><subj-group subj-group-type="heading"><subject>PI20190300000_70231786.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  草酸艾司西酞普兰治疗卒中后抑郁疗效的Mate分析
  The Efficacy of Escitalopram Oxalate in the Treatment of Post-Stroke Depression of Meta-Analysis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>武</surname><given-names>军祥</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>师</surname><given-names>宁</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>梦园</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>杰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>17</day><month>04</month><year>2019</year></pub-date><volume>08</volume><issue>03</issue><fpage>134</fpage><lpage>144</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：系统评价草酸艾司西酞普兰治疗卒中后抑郁(post-stroke depression)的效果。方法：检索PubMed、Embase、Cochrane Library、Web of Science、SinoMed、中国知网、万方数据库、维普数据库等数据库，限定时间为2010年1月~2018年10月31日，文献类型为随机对照，实验组为草酸艾司西酞普兰(escitalopram oxalate ESO)治疗或其联合心理治疗或其他常规治疗，对照组为其他抗抑郁药物或其联合心理治疗或其他常规治疗。对所提结果进行文献偏倚质量评价以及资料提取后用stata15.0软件进行meta分析。结果：依研究要求最终纳入15篇文献，总样本n = 1287例，其实验组n = 645例，对照组n = 642例。HAMD于第2、4、6、8周实验组相对对照组评分分别为[SMD = −0.372 95% CI (−0.944 0.200), p = 0.202]、[SMD = −1.191 95% CI (−1.894 −0.489), p = 0.001]、[SMD = −0.213 95% CI (−0.463 0.036), p = 0.093]、[SMD = −0.995 95% CI (−1.736 −0.254), p = 0.008]，第2周和第6周无统计学意义，可能与观察时间、评分准确度以及治疗措施有关，而第4、8周有统计学意义，组间差异有统计学意义,实验组比对照组能明显降低PSD抑郁程度，同时NIHSS评分[SMD = −1.287 95% CI (−1.775 -0.800), p = 0.000]，组间差异有统计学意义，实验组较对照组神经功能恢复较好。MMSE评分[SMD = 1.405 95% CI (1.104 1.707), p = 0.000]，组间差异有统计学意义，实验组较对照组智力及认知功能缺损恢复较好。以及实验组无效率明显低于对照组[SMD = 3.784 95% CI (1.836 7.7986), p = 0.000]，差异有统计学意义。研究组的异质性较大，经亚组分析发现与发表年份有关，纳入研究组在治疗期间均出现不良反应，但均在一周内消失，能继续完成实验。结论：实验组较对照组能显著降低PSD的抑郁程度、促进神经功能恢复以及提高认知水平，但是本研究相对纳入研究文献质量水平有限，结论有待进一步验证。 Objective: To systematically evaluate the efficacy of escitalopram oxalate in the treatment of post-stroke depression (post-stroke depression). Methods: The databases of PubMed, Embase, Cochrane Library, Web of Science, SinoMed, China Knowledge Network, Wanfang database and VIP databases were retrieved, which was limited to January 2010-October 31, 2018, and the document type was randomized, the experimental group was treated with oxalic acid escitalopram (escitalopram oxalate ESO) or its combined psychotherapy or other routine treatment, and the control group was other antidepressants or their combined psychotherapy or other routine treatment. The results of literature bias quality evaluation and data extraction were used to carry out meta analysis with stata15.0 software. Results: According to the research requirements, 15 literatures were finally included, the total sample n = 1287 case, the experimental group n = 645 case, the control group n = 642 case. The scores of HAMD in the experimental group in the 2, 4, 6 and 8 weeks were compared with those of the control group, [SMD = −0.372 95% CI (−0.944 0.200), p = 0.202], [SMD = −1.191 95% CI (−1.894 −0.489), p = 0.001], [SMD = −0.213 95% CI (−0.463 0.036), p = 0.093], [SMD = −0.995 95% CI (−1.736 −0.254), p = 0.008]. The statistical significance of the 2nd week and the 6th Friday may be related to the observation time, the accuracy of the score and the treatment measures, and the 4th and 8th weeks have statistical significance. The experimental group can significantly reduce the degree of PSD depression compared with the control group. At the same time, the NIHSS score [SMD = −1.287 95% CI (−1.775 −0.800), p = 0.000], the difference between the groups was statistically significant, and the experimental group was better than the control group. The MMSE score [SMD = 1.405 95% CI (1.104 1.707), p = 0.000], the difference between the groups was statistically significant, and the experimental group recovered better than the control group. The effectiveness of the experimental group was significantly lower than that of the control group [SMD = 3.784 95% CI (1.836 7.7986), p = 0.000], and the difference was statistically significant. The heterogeneity of the study group was large. The subgroup analysis found that it was related to the year of publication. The study group had adverse reactions during the treatment period, but all disappeared within one week and the experiment could be continued. Conclusion: The experimental group can significantly reduce the Depression degree of PSD, promote the recovery of neurological function and improve the cognitive level compared with the control group, but the quality level of the literature is limited and the conclusion needs to be further verified. 
  
 
</p></abstract><kwd-group><kwd>草酸艾司西酞普兰，脑卒中，抑郁，Meta分析, Escitalopram Oxalate</kwd><kwd> Stork</kwd><kwd> Depression</kwd><kwd> Meta-Analysis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>草酸艾司西酞普兰治疗卒中后抑郁疗效的 Mate分析</title><p>武军祥，师 宁<sup>*</sup>，李梦园，刘 杰</p><p>延安大学附属医院，陕西 延安</p><disp-formula id="hanspub.30513-formula25"><graphic xlink:href="//html.hanspub.org/file/13-1710179x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年5月10日；录用日期：2019年5月22日；发布日期：2019年5月29日</p><disp-formula id="hanspub.30513-formula26"><graphic xlink:href="//html.hanspub.org/file/13-1710179x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：系统评价草酸艾司西酞普兰治疗卒中后抑郁(post-stroke depression)的效果。方法：检索PubMed、Embase、Cochrane Library、Web of Science、SinoMed、中国知网、万方数据库、维普数据库等数据库，限定时间为2010年1月~2018年10月31日，文献类型为随机对照，实验组为草酸艾司西酞普兰(escitalopram oxalate ESO)治疗或其联合心理治疗或其他常规治疗，对照组为其他抗抑郁药物或其联合心理治疗或其他常规治疗。对所提结果进行文献偏倚质量评价以及资料提取后用stata15.0软件进行meta分析。结果：依研究要求最终纳入15篇文献，总样本n = 1287例，其实验组n = 645例，对照组n = 642例。HAMD于第2、4、6、8周实验组相对对照组评分分别为[SMD = −0.372 95% CI (−0.944 0.200), p = 0.202]、[SMD = −1.191 95% CI (−1.894 −0.489), p = 0.001]、[SMD = −0.213 95% CI (−0.463 0.036), p = 0.093]、[SMD = −0.995 95% CI (−1.736 −0.254), p = 0.008]，第2周和第6周无统计学意义，可能与观察时间、评分准确度以及治疗措施有关，而第4、8周有统计学意义，组间差异有统计学意义,实验组比对照组能明显降低PSD抑郁程度，同时NIHSS评分[SMD = −1.287 95% CI (−1.775 -0.800), p = 0.000]，组间差异有统计学意义，实验组较对照组神经功能恢复较好。MMSE评分[SMD = 1.405 95% CI (1.104 1.707), p = 0.000]，组间差异有统计学意义，实验组较对照组智力及认知功能缺损恢复较好。以及实验组无效率明显低于对照组[SMD = 3.784 95% CI (1.836 7.7986), p = 0.000]，差异有统计学意义。研究组的异质性较大，经亚组分析发现与发表年份有关，纳入研究组在治疗期间均出现不良反应，但均在一周内消失，能继续完成实验。结论：实验组较对照组能显著降低PSD的抑郁程度、促进神经功能恢复以及提高认知水平，但是本研究相对纳入研究文献质量水平有限，结论有待进一步验证。</p><p>关键词 :草酸艾司西酞普兰，脑卒中，抑郁，Meta分析</p><disp-formula id="hanspub.30513-formula27"><graphic xlink:href="//html.hanspub.org/file/13-1710179x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/13-1710179x8_hanspub.png" /> <img src="//html.hanspub.org/file/13-1710179x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>就目前而言，老龄化仍然是一个不可忽视的全球问题，面临严峻疾病挑战和全球卫生健康问题，全球面临卒中流行，尽管目前卒中发病率较稳定，死亡率下降，但因卒中丧失的残疾调整寿命和与中风相关死亡人数却在不断增加 [<xref ref-type="bibr" rid="hanspub.30513-ref1">1</xref>] ，且卒中有年轻化的趋势发展，全球负担并非乐观 [<xref ref-type="bibr" rid="hanspub.30513-ref2">2</xref>] 。</p><p>卒中后抑郁被精神学家认识超过100多年，认为其病因可能与遗传和表观遗传变异、白质病变、脑血管失调、神经可塑性改变和谷氨酸神经传递的改变等相关 [<xref ref-type="bibr" rid="hanspub.30513-ref3">3</xref>] 。最新荟萃分析表明在卒中后5年的任何时间点约31%的患者可发展为抑郁症，且总患病率为29% [<xref ref-type="bibr" rid="hanspub.30513-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref5">5</xref>] ，卒中后抑郁为为卒中后常见并发症之一，以持久且显著的心境低落的为主要临床表现，严重影响卒中患者康复进程、预后水平 [<xref ref-type="bibr" rid="hanspub.30513-ref6">6</xref>] ，甚者增加死亡率，有研究表明，PSD患者死亡率约为一般卒中患者数倍高 [<xref ref-type="bibr" rid="hanspub.30513-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref7">7</xref>] 。草酸艾司西酞普兰(ESO)作为一种5-HT再摄取抑制(SSRI)类抗抑郁药，一项回顾性研究表明草酸艾司西酞普兰在治疗PSD中显示出较好疗效和良好的安全性 [<xref ref-type="bibr" rid="hanspub.30513-ref8">8</xref>] 。通过文献查阅，对于ESO治疗PSD报道较多，且局限于小样本分析，此次分析我们将通过文献数据着手，采用meta分析对草酸艾司西酞普兰治疗卒中后抑郁疗效进行系统评价，为PSD的药物治疗提供相关临床意义。</p></sec><sec id="s4"><title>2. 资料及方法</title><sec id="s4_1"><title>2.1. 文献类型</title><p>随机对照试验(randomized controlled trials RCT)，包括中、英文。限定时间为2010年1月~2018年10月31日。</p><sec id="s4_1_1"><title>2.1.1. 纳入排除标准</title><p>首次脑卒中且大龄 &gt; 20岁，且符合1995年“全国第四届脑血管病会议”制定的脑血管诊断标准 [<xref ref-type="bibr" rid="hanspub.30513-ref9">9</xref>] 、1978年世界卫生组织制定标准 [<xref ref-type="bibr" rid="hanspub.30513-ref10">10</xref>] ，并经头颅CT或MRI确认，还需符合《中国精神障碍分类与诊断标准》第3版 [<xref ref-type="bibr" rid="hanspub.30513-ref11">11</xref>] 或《精神疾病诊断与统计手册》第IV版或第V版。排出标准：1) 重复文献；2) 严重昏迷、认知功能障碍以及其他躯体症状障碍；3) 发病之前有抑郁症。</p></sec><sec id="s4_1_2"><title>2.1.2. 干预措施</title><p>实验组为接受ESO治疗或ESO + 常规治疗或其他治疗，对照组为无ESO治疗或常规治疗或其他治疗。</p></sec><sec id="s4_1_3"><title>2.1.3. 干预措施</title><p>主效应观察指标采用汉密顿抑郁量表(Hamilton Depression Scale HAMD)第17、21和24版，且评分 ≥ 17分，评估抑郁改善程度，次效应观察指标为基于美国研究院脑卒中评定量表(NationalInstitute of Health Stroke Scale NIHSS)评估神经功能恢复，汉密顿焦虑量表(Hamilton Anxiey Scale, HAMA)评估焦虑改善情况，简易精神状态检查表(Minimum Mental State Examination MMSE)评估认知改善 [<xref ref-type="bibr" rid="hanspub.30513-ref12">12</xref>] 。</p></sec></sec><sec id="s4_2"><title>2.2. 文献类型</title><p>检索PubMed、Embase、Cochrane Library、Web of Science、SinoMed、中国知网、万方数据库、维普数据库等数据库。中文检索词包括“脑卒中/中风/脑血管病、抑郁/抑郁症、草酸艾司西酞普兰、随机”，英文检索采用主题词 + 自由词的方式进行，主题词和自由词的确定通过检索pubmed主题谱(Mesh)获得，整个过程由1名研究研员独立进行。Pubmed检索关键词及策略。见框1。</p></sec><sec id="s4_3"><title>2.3. 质量控制与资料提取</title><p>此项由2位研究者独立筛选、并采用采用Cochrane偏倚风险评估工具，对所纳入资料进依据是否正确随机、是否采用盲法、是否分配隐匿、是否描述失访以及发表偏倚等五个方面进行，当有分歧出现，通过第3位研究者参入进行讨论协助。资料提取包含：第一作者、文献发表年份、受试者性别、样本量、</p><disp-formula id="hanspub.30513-formula28"><graphic xlink:href="//html.hanspub.org/file/13-1710179x10_hanspub.png"  xlink:type="simple"/></disp-formula><p>Frame 1. Pubmed search keywords and strategie</p><p>框1. Pubmed检索关键词及策略</p><p>研究类型、草酸艾司西酞普兰干预组、对照组治疗情况和治疗结果等内容。</p></sec><sec id="s4_4"><title>2.4. 统计学方法</title><p>尽对所提取数据用Stata15.0软件进行，对二分类变量类型数据采用(oddsratio, OR)以及95%置信区间(confidence interval CI)表示；对于连续性变量型数据采用标准化均数差(standardized mean difference SMD)以及95%置信区间(CI)表示。数据间的异质性采用I2值的大小选用效应模型，若I2 &gt; 50%采用随机效应模型，若I2 ≤ 50%采用固定效应模型。探究异质性来源采用stata15.0软件性行meta亚组分析，必要时进一步予meta回归分析。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 文献筛选</title><p>通过检索共获取文献160篇，中文114篇，英文46篇，经按纳入和排除标准阅读全文后，最终纳入</p><p>图1. 文献筛选流程图</p><p>文献15篇 [<xref ref-type="bibr" rid="hanspub.30513-ref12">12</xref>] - [<xref ref-type="bibr" rid="hanspub.30513-ref26">26</xref>] ，其中文15篇，英文0篇，纳入总样本n = 1287例，其实验组n = 645例，对照组n = 642例。纳入研究基本情况见表1。文献筛选流程见图1。</p></sec><sec id="s5_2"><title>3.2. 纳入文献偏倚风险评估</title><p>所有纳入研究受试者均进行随机分配，但都未具体说明分配方式，15项研究均未提及分配隐匿、盲法设计，但都未出现失访，结果指标记录完整，均数均可进行meta分析。见表2。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> General situation of inclusion in the literatur</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >作者</th><th align="center" valign="middle"  rowspan="2"  >年份</th><th align="center" valign="middle"  rowspan="2"  >总数</th><th align="center" valign="middle"  rowspan="2"  >样本E</th><th align="center" valign="middle"  rowspan="2"  >病程E</th><th align="center" valign="middle"  rowspan="2"  >年龄E</th><th align="center" valign="middle"  colspan="2"  >干预措施</th><th align="center" valign="middle"  colspan="4"  >干预时间(周!)</th></tr></thead><tr><td align="center" valign="middle" >E</td><td align="center" valign="middle" >C</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle" >王晓峰<sup> </sup></td><td align="center" valign="middle" >2010</td><td align="center" valign="middle" >126</td><td align="center" valign="middle" >63/63</td><td align="center" valign="middle" >2.94 &#177; 3.37/2.72 &#177; 3.51</td><td align="center" valign="middle" >63.3 &#177; 6.49/65.7 &#177; 7.13</td><td align="center" valign="middle" >A</td><td align="center" valign="middle" >氯米帕明</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >!</td></tr><tr><td align="center" valign="middle" >郭力等<sup> </sup></td><td align="center" valign="middle" >2012</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" >36/33</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >36.5 &#177; 11.8/25.76 &#177; 3.90</td><td align="center" valign="middle" >A</td><td align="center" valign="middle" >文拉法辛</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" >!</td></tr><tr><td align="center" valign="middle" >高学军<sup> </sup></td><td align="center" valign="middle" >2013</td><td align="center" valign="middle" >90</td><td align="center" valign="middle" >45/45</td><td align="center" valign="middle" >5.1 &#177; 3.2/4.8 &#177; 3.5</td><td align="center" valign="middle" >40.0 &#177; 12.8/40.5 &#177; 13.1</td><td align="center" valign="middle" >A</td><td align="center" valign="middle" >西酞普兰</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" >!</td></tr><tr><td align="center" valign="middle" >潘继英<sup> </sup></td><td align="center" valign="middle" >2013</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >35/35</td><td align="center" valign="middle" >7.9 &#177; 1.9/7.4 &#177; 1.8</td><td align="center" valign="middle" >67.9 &#177; 7.1/66.1 &#177; 6.8</td><td align="center" valign="middle" >A</td><td align="center" valign="middle" >舍曲林</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >王淑茗等<sup> </sup></td><td align="center" valign="middle" >2013</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >34/34</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >A</td><td align="center" valign="middle" >空白组</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >刘继<sup> </sup></td><td align="center" valign="middle" >2013</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >30/30</td><td align="center" valign="middle" >13.5 &#177; 2.3/11.4 &#177; 8.1</td><td align="center" valign="middle" >51.23 &#177; 2.57/49.2 &#177; 8.1</td><td align="center" valign="middle" >A</td><td align="center" valign="middle" >舍曲林</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >赵新慧等<sup> </sup></td><td align="center" valign="middle" >2014</td><td align="center" valign="middle" >98</td><td align="center" valign="middle" >49/49</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >64.03 &#177; 12.41/61.47 &#177; 12.59</td><td align="center" valign="middle" >A + 常</td><td align="center" valign="middle" >常</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >!</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >!</td></tr><tr><td align="center" valign="middle" >吴志明等<sup> </sup></td><td align="center" valign="middle" >2014</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >34/34</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >A</td><td align="center" valign="middle" >帕罗西汀</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >蒋丹丹<sup> </sup></td><td align="center" valign="middle" >2015</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >20/20</td><td align="center" valign="middle" >18-80/21-85天</td><td align="center" valign="middle" >56.00 &#177; 7.2/58.40 &#177; 10.23</td><td align="center" valign="middle" >A + 常 + 康复</td><td align="center" valign="middle" >常 + 康复</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >!</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >李仲光等<sup> </sup></td><td align="center" valign="middle" >2016</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" >36/36</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >66.2 &#177; 1.9</td><td align="center" valign="middle" >A</td><td align="center" valign="middle" >帕罗西汀</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" >!</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >李继等<sup> </sup></td><td align="center" valign="middle" >2016</td><td align="center" valign="middle" >120</td><td align="center" valign="middle" >60/60</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >62.02 &#177; 9.80/62.35 &#177; 9.31</td><td align="center" valign="middle" >A + 常 + 康复</td><td align="center" valign="middle" >常 + 康复 + 安慰剂</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >!</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >邓豪斌</td><td align="center" valign="middle" >2018</td><td align="center" valign="middle" >80</td><td align="center" valign="middle" >40/40</td><td align="center" valign="middle" >14.2 &#177; 4.7</td><td align="center" valign="middle" >68.5&#177;6.8</td><td align="center" valign="middle" >A + 常</td><td align="center" valign="middle" >米氮平 + 常</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >!</td></tr><tr><td align="center" valign="middle" >周红平</td><td align="center" valign="middle" >2018</td><td align="center" valign="middle" >92</td><td align="center" valign="middle" >46/46</td><td align="center" valign="middle" >3-17/3-16周</td><td align="center" valign="middle" >58.19 &#177; 5.67/57.92 &#177; 5.43</td><td align="center" valign="middle" >A + 常</td><td align="center" valign="middle" >黛力新 + 常</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >!</td></tr><tr><td align="center" valign="middle" >刘伟等</td><td align="center" valign="middle" >2018</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >60/60</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >A + 常</td><td align="center" valign="middle" >疏肝解郁胶囊 + 常</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >!</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >刘永珍</td><td align="center" valign="middle" >2018</td><td align="center" valign="middle" >108</td><td align="center" valign="middle" >54/54</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >63.2 &#177; 9.6/60.1 &#177; 11.9</td><td align="center" valign="middle" >A</td><td align="center" valign="middle" >黛力新</td><td align="center" valign="middle" >!</td><td align="center" valign="middle"  colspan="3"  >24周</td></tr></tbody></table></table-wrap><p>表1. 纳入文献一般情况</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Methodology and quality evaluation included in the stud</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" >作者年份</th><th align="center" valign="middle" >是否随机</th><th align="center" valign="middle" >是否分配隐匿</th><th align="center" valign="middle" >材料完整性</th><th align="center" valign="middle" >盲法设计</th><th align="center" valign="middle" >发表偏倚</th><th align="center" valign="middle" >是否退出实验</th></tr></thead><tr><td align="center" valign="middle" >王晓峰2010 [<xref ref-type="bibr" rid="hanspub.30513-ref12">12</xref>]</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >完整</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >低</td><td align="center" valign="middle" >否</td></tr><tr><td align="center" valign="middle" >郭力等2012 [<xref ref-type="bibr" rid="hanspub.30513-ref13">13</xref>]</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >完整</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >低</td><td align="center" valign="middle" >否</td></tr><tr><td align="center" valign="middle" >高学军2013 [<xref ref-type="bibr" rid="hanspub.30513-ref14">14</xref>]</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >完整</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >低</td><td align="center" valign="middle" >否</td></tr><tr><td align="center" valign="middle" >潘继英2013 [<xref ref-type="bibr" rid="hanspub.30513-ref15">15</xref>]</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >完整</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >低</td><td align="center" valign="middle" >否</td></tr><tr><td align="center" valign="middle" >王淑茗等2013 [<xref ref-type="bibr" rid="hanspub.30513-ref16">16</xref>]</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >完整</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >低</td><td align="center" valign="middle" >否</td></tr><tr><td align="center" valign="middle" >刘继2013 [<xref ref-type="bibr" rid="hanspub.30513-ref17">17</xref>]</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >完整</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >低</td><td align="center" valign="middle" >否</td></tr><tr><td align="center" valign="middle" >赵新慧2014 [<xref ref-type="bibr" rid="hanspub.30513-ref18">18</xref>]</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >完整</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >低</td><td align="center" valign="middle" >否</td></tr><tr><td align="center" valign="middle" >吴志明等2014 [<xref ref-type="bibr" rid="hanspub.30513-ref19">19</xref>]</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >完整</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >低</td><td align="center" valign="middle" >否</td></tr><tr><td align="center" valign="middle" >蒋丹丹2015 [<xref ref-type="bibr" rid="hanspub.30513-ref20">20</xref>]</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >完整</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >低</td><td align="center" valign="middle" >否</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >李仲光等2016 [<xref ref-type="bibr" rid="hanspub.30513-ref21">21</xref>]</th><th align="center" valign="middle" >是</th><th align="center" valign="middle" >未描述</th><th align="center" valign="middle" >完整</th><th align="center" valign="middle" >未描述</th><th align="center" valign="middle" >低</th><th align="center" valign="middle" >否</th></tr></thead><tr><td align="center" valign="middle" >李继等2016 [<xref ref-type="bibr" rid="hanspub.30513-ref22">22</xref>]</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >完整</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >低</td><td align="center" valign="middle" >否</td></tr><tr><td align="center" valign="middle" >邓豪斌2018 [<xref ref-type="bibr" rid="hanspub.30513-ref23">23</xref>]</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >完整</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >低</td><td align="center" valign="middle" >否</td></tr><tr><td align="center" valign="middle" >周红平2018 [<xref ref-type="bibr" rid="hanspub.30513-ref24">24</xref>]</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >完整</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >低</td><td align="center" valign="middle" >否</td></tr><tr><td align="center" valign="middle" >刘伟等2018 [<xref ref-type="bibr" rid="hanspub.30513-ref25">25</xref>]</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >完整</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >低</td><td align="center" valign="middle" >否</td></tr><tr><td align="center" valign="middle" >刘永珍2018 [<xref ref-type="bibr" rid="hanspub.30513-ref26">26</xref>]</td><td align="center" valign="middle" >是</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >完整</td><td align="center" valign="middle" >未描述</td><td align="center" valign="middle" >低</td><td align="center" valign="middle" >否</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. 纳入研究的方法学及质量评价</p></sec><sec id="s5_3"><title>3.3. Meta分析结果</title><sec id="s5_3_1"><title>3.3.1. HAMD评分</title><p>英15项研究 [<xref ref-type="bibr" rid="hanspub.30513-ref13">13</xref>] - [<xref ref-type="bibr" rid="hanspub.30513-ref27">27</xref>] 以均数&#177;标准差的形式列出了实验组和对照组治疗前后的HAMD得分，且给出治疗第2、4、6、8周后的评分结果，研究发现异质性较高，采用随机效应模型，结果表明，9项研究 [<xref ref-type="bibr" rid="hanspub.30513-ref13">13</xref>] - [<xref ref-type="bibr" rid="hanspub.30513-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref27">27</xref>] 报道两组治疗第2周后HAMD评分，[SMD = −0.372 95% CI (−0.944 0.200), p = 0.202]，第2周p &gt; 0.05，无统计学意义，可能与观察时间太短相关；12项研究[<xref ref-type="bibr" rid="hanspub.30513-ref13">13</xref>]-[<xref ref-type="bibr" rid="hanspub.30513-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref26">26</xref>]报道两组治疗第4周后HAMD评分，[SMD = −1.191 95% CI (−1.894 −0.489), p = 0.001]，组间有统计学意义；7项研究 [<xref ref-type="bibr" rid="hanspub.30513-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref22">22</xref>] 报道两组治疗第6周后HAMD评分，[SMD = −0.213 95% CI (−0.463 0.036), p = 0.093]，第6周p &gt; 0.05，无统计学意义，可能与药物作用、量表测评准确性相关；7项研究 [<xref ref-type="bibr" rid="hanspub.30513-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref26">26</xref>] 报道两组治疗第8周后HAMD评分，[SMD = −0.995 95% CI (−1.736 −0.254), p = 0.008]，组间有统计学意义。第4和8周p &lt; 0.05，具有统计学意义，治疗组较对照组的抗抑郁情况显著。见图2。</p></sec><sec id="s5_3_2"><title>3.3.2. NIHSS评分</title><p>纳入文献共有2项 [<xref ref-type="bibr" rid="hanspub.30513-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref26">26</xref>] 以均数&#177;标准差的形式列出了实验组和对照组治疗前后的NIHSS得分，研究间异质性较大，采用随机效应模型进行Meta分析。结果表明实验组较对照组神经功能恢复较好，组间差异有统计学意义[SMD = −1.287 95% CI (−1.775 −0.800), p = 0.000]。见图3。</p></sec><sec id="s5_3_3"><title>3.3.3. HAMA评分</title><p>纳入文献共有3项 [<xref ref-type="bibr" rid="hanspub.30513-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref27">27</xref>] 以均数&#177;标准差的形式列出了实验组和对照组治疗前后的HAMA得分，报道两组治疗第2周和第4周后HAMD评分，研究间异质性小，采用固定效应模型进行Meta分析，第6周异质性较大，采用随机效应模型进行Meta分析。3项研究 [<xref ref-type="bibr" rid="hanspub.30513-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref27">27</xref>] [SMD = −0.018 95% CI (−0.273 0.236), p = 0.888]；3项研究 [<xref ref-type="bibr" rid="hanspub.30513-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref27">27</xref>] 报道两组治疗第4周后HAMD评分，[SMD = 0.000 95% CI (−0.276 0.276), p = 0.999]；3项研究 [<xref ref-type="bibr" rid="hanspub.30513-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref27">27</xref>] 报道两组治疗第6周后HAMD评分，[SMD = 0.175 95% CI (−0.120 0.436), p = 0.464]，组间差异无有统计学意义。见图4。</p></sec><sec id="s5_3_4"><title>3.3.4. MMSE评分</title><p>中纳入文献共有2项 [<xref ref-type="bibr" rid="hanspub.30513-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref26">26</xref>] 以均数&#177;标准差的形式列出了实验组和对照组治疗前后的NIHSS得分，研究间异质性较小，采用固定效应模型进行Meta分析。结果显示组间差异有统计学意义[SMD = 1.405 95% CI (1.104 1.707), p = 0.000]，表明实验组较对照组智力及认知功能缺损恢复较好。见图5。</p></sec><sec id="s5_3_5"><title>3.3.5. 草酸艾司西酞普兰治疗PSD无效率</title><p>共五项研究记录有效率资料，发现研究间异质性小，采用固定效应模型行meta分析。结果显示[SMD = 3.784 95% CI (1.836 7.7986), p = 0.000]，差异有统计学意义，ESO无效率明显低于对照组。见图6。</p><p>图2. 实验组和对照组第2、4、6、8周HAMD评分的Meta分析森林图</p><p>图3. 实验组和对照组NIHSS评分的Meta分析森林图</p><p>图4. 实验组和治疗组第2、4、6周HAMA评分的Meta分析森林图</p><p>图5. 实验组和对照组MMSE评分的Meta分析森林图</p><p>图6. 实验组和对照组治疗PSD无效率的meta分析森林图</p></sec></sec></sec><sec id="s6"><title>4. 讨论</title><p>卒中是一类因脑缺血或出血引发的脑功能障碍的疾病，超过1天时间未经干预的卒中患者，其死亡率有增加的风险，中风是全球第三大死因，预计于2030年将增至2300万例(1200万人死亡，7000万幸存者)，于工业化国家死因居第三，尽管年龄 &lt; 65岁以下患者比例大幅增加，但更令人担忧的是，中风是导致慢性，严重成人残疾的主要原因，需要长期的康复训练。增加家庭和社会严重人类问题以及巨大的公共财务负担 [<xref ref-type="bibr" rid="hanspub.30513-ref28">28</xref>] [<xref ref-type="bibr" rid="hanspub.30513-ref29">29</xref>] 。PSD作为卒中后精神障碍常见并发症之一，Ayerbe发现PSD累计发病率为55% [<xref ref-type="bibr" rid="hanspub.30513-ref5">5</xref>] ，Hackett和Anderson荟萃分析显示PSD的汇总频率估计为33% [<xref ref-type="bibr" rid="hanspub.30513-ref30">30</xref>] ，据Jun研究分析，不同类型脑梗死患者的PSD发生率有很大差异，前循环较后循环PSD发生率相对高，且认知受损相对严重 [<xref ref-type="bibr" rid="hanspub.30513-ref31">31</xref>] 。且据Backhouse对11,884例患者的系统评价和meta分析显示，卒中前抑郁症显着增加了卒中后抑郁的几率，从而提醒我们卒中前抑郁远远不可忽视 [<xref ref-type="bibr" rid="hanspub.30513-ref32">32</xref>] 。PSD与身体和认知恢复，功能结果和生活质量的进一步恶化密切相关，其主要影响患者参与康复治疗的能力。选择性5-羟色胺再摄取抑制剂(SSRI)药物主要用于抑郁症的治疗，有关研究表明其对PSD也有较好的效果 [<xref ref-type="bibr" rid="hanspub.30513-ref33">33</xref>] ，可通过其外部分子调节独立于抑制的特定效应改善脑卒中后大脑的可塑性，其可对PSD减少3个月时发现的临床缺陷 [<xref ref-type="bibr" rid="hanspub.30513-ref34">34</xref>] 。酸艾司西酞普兰作为一种SSRI类药物有较好的疗效和良好的安全性，不仅可降低PSD的抑郁程度，而且能提高患者神经功能恢复和认知水平，促进卒中后患者康复治疗，减少死亡率，减轻患者家属和社会医疗负担。但是随着病程延长和进展，相对患者的心理负担会加重，出现治疗希望率降低甚至渺茫感，心理应激矛盾情绪激化，可能会更容易或者在原有疾病基础上加重心境精神问题，这就需要我们临床医生、家庭成员以及社会的关注，给予关心、温暖和理解等心理治疗增加患者治疗期望，降低PSD患者无助、无用感，以心理治疗、药物联合达到治疗的较好效果。通过此次meta分析，本研究共纳入15项研究，我们对ESO治疗PSD持较肯定态度，但是本次研究存在一定的缺陷：所纳入研究并非具体描述随机内容，且均没有隐匿及盲法设置，纳入文献的治疗相对存在一定缺陷。另外纳入研究文献观察效果时间并未完全一致，也可能对本研究产生一定偏倚。因此，为进一步验证，尚需大样本、多中心随机双盲对照试验，以更好的指导PSD的临床治疗。</p></sec><sec id="s7"><title>文章引用</title><p>武军祥,师 宁,李梦园,刘 杰. 草酸艾司西酞普兰治疗卒中后抑郁疗效的Mate分析 The Efficacy of Escitalopram Oxalate in the Treatment of Post-Stroke Depression of Meta-Analysis[J]. 药物资讯, 2019, 08(03): 134-144. https://doi.org/10.12677/PI.2019.83017</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.30513-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Hankey, G.J. (2017) Stroke. The Lancet, 389, 641-654. &lt;br&gt;https://doi.org/10.1016/S0140-6736(16)30962-X</mixed-citation></ref><ref id="hanspub.30513-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Feigin, V.L., Norrving, B. and Mensah, G.A. (2017) Global Burden of Stroke. Circulation Research, 120, 439-448.  
&lt;br&gt;https://doi.org/10.1161/CIRCRESAHA.116.308413</mixed-citation></ref><ref id="hanspub.30513-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Robinson, R.G. and Jorge, R.E. (2016) Post-Stroke De-pression: A Review. American Journal of Psychiatry, 173, 221-231. &lt;br&gt;https://doi.org/10.1176/appi.ajp.2015.15030363</mixed-citation></ref><ref id="hanspub.30513-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Hackett, M.L. and Pickles, K. (2014) Part I: Frequency of Depression after Stroke: An Updated Systematic Review and Meta-Analysis of Observational Studies. International Journal of Stroke, 9, 1017-1025.  
&lt;br&gt;https://doi.org/10.1111/ijs.12357</mixed-citation></ref><ref id="hanspub.30513-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ayerbe, L., Ayis, S., Wolfe, C.D., et al. (2013) Natural History, Predictors and Outcomes of Depression after Stroke: Systematic Review and Meta-Analysis. The British Journal of Psychiatry, 202, 14-21.  
&lt;br&gt;https://doi.org/10.1192/bjp.bp.111.107664</mixed-citation></ref><ref id="hanspub.30513-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Wei, N., Yong, W., Li, X., et al. (2015) Post-Stroke Depression and Lesion Location: A Systematic Review. Journal of Neurology, 262, 81-90. &lt;br&gt;https://doi.org/10.1007/s00415-014-7534-1</mixed-citation></ref><ref id="hanspub.30513-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Espárrago Llorca, G., Castilla-Guerra, L., Fernández Moreno, M.C., et al. (2015) Post-Stroke Depression: An Update. Neurología, 30, 23-31. &lt;br&gt;https://doi.org/10.1016/j.nrl.2012.06.008</mixed-citation></ref><ref id="hanspub.30513-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Xu, J.H. and Jiang, P. (2018) Efficacy of Escitalopram Oxalate for Patients with Post-Stroke Depression. Medicine (Baltimore), 97, e0219. &lt;br&gt;https://doi.org/10.1097/MD.0000000000010219</mixed-citation></ref><ref id="hanspub.30513-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">王新德. 各类脑血管疾病诊断要点[J]. 中华神经科杂志, 1996, 29(6): 379-380.</mixed-citation></ref><ref id="hanspub.30513-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (1978) Cerebrovascular Disorders: A Clinical and Research Classification. World Health Organization, Geneva.</mixed-citation></ref><ref id="hanspub.30513-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会精神科分会. CCMD-3中国精神障碍分类与诊断标准[J]. 济南: 山东科学技术出版社, 2001: 64-67.</mixed-citation></ref><ref id="hanspub.30513-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">孙鼎明, 袁勇贵, 张志珺. 卒中后抑郁诊断及量表的使用[J]. 中国卒中杂志, 2007, 2(11): 916-918.</mixed-citation></ref><ref id="hanspub.30513-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">王晓峰, 杨放如. 草酸艾司西酞普兰与氯米帕明治疗脑梗死后抑郁症的对照研究[J]. 临床医学, 2010, 23(7): 106.</mixed-citation></ref><ref id="hanspub.30513-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">郭力, 白渊翰, 孙润珠. 盐酸文拉法辛和草酸艾司西酞普兰治疗抑郁症的对照研究[J]. 神经疾病与精神卫生, 2012, 12(2): 114-116.</mixed-citation></ref><ref id="hanspub.30513-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">高学军. 草酸艾司西酞普兰应用于脑卒中后抑郁治疗的有效性分析[J]. 中国实用神经疾病杂志, 2013, 16(14): 16-18.</mixed-citation></ref><ref id="hanspub.30513-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">潘继英, 全传升. 草酸艾司西酞普兰治疗脑卒中后抑郁的疗效分析[J]. 神经疾病与精神卫生, 2013, 13(4): 387-388.</mixed-citation></ref><ref id="hanspub.30513-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">王淑茗, 吴志明, 任传波. 草酸艾司西酞普兰治疗脑卒中后抑郁的研究[J]. 医药前沿, 2013(16): 162.</mixed-citation></ref><ref id="hanspub.30513-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">刘继, 王青. 草酸艾司西酞普兰与舍曲林治疗脑卒中后抑郁症对照观察[J]. 中国实用神经疾病杂志, 2013, 16(15): 85-86.</mixed-citation></ref><ref id="hanspub.30513-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">赵新慧, 温进哲, 袁芳. 草酸艾司西酞普兰预防卒中后抑郁的临床观察[J]. 现代药物与临床, 2014, 29(3): 269-272.</mixed-citation></ref><ref id="hanspub.30513-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">吴志明, 任传波. 草酸艾司西酞普兰在脑卒中后抑郁的临床应用[J]. 中国保健营养, 2014, 24(3): 1539-1540.</mixed-citation></ref><ref id="hanspub.30513-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">蒋丹丹, 彭辰, 陆宇超. 草酸艾司西酞普兰对脑卒中后抑郁患者运动功能的影响[J]. 按摩与康复医学, 2015(3): 76-77.</mixed-citation></ref><ref id="hanspub.30513-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">李仲光, 伏强, 张冀燕, 等. 草酸艾司西酞普兰与盐酸帕罗西汀治疗脑卒中后抑郁临床比较[J]. 医药前沿, 2016, 6(24): 165-167.</mixed-citation></ref><ref id="hanspub.30513-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">李继, 王建军, 李烨, 张文宁, 赵静霞. 草酸艾司西酞普兰对脑卒中后抑郁、认知及神经功能的影响[J]. 河北医科大学学报, 2017, 38(5): 589-592.</mixed-citation></ref><ref id="hanspub.30513-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">邓毫斌. 草酸艾司西酞普兰联合米氮平治疗卒中后抑郁疗效观察[J]. 临床合理用药杂志, 2018(11): 38-39.</mixed-citation></ref><ref id="hanspub.30513-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">周红平, 曹栋, 韩淑辉, 王杰. 草酸艾司西酞普兰联合黛力新对脑卒中后抑郁障碍患者的疗效及对血清指标的影响[J]. 国际精神病学杂志, 2018, 45(4): 707-710.</mixed-citation></ref><ref id="hanspub.30513-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">刘伟, 赵静雅, 尚小龙, 吴超. 草酸艾司西酞普兰治疗卒中后抑郁的疗效及其对患者MMSE评分、ADL评分的影响[J]. 国际精神病学杂志, 2018(1): 128-130.</mixed-citation></ref><ref id="hanspub.30513-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">刘永珍, 尹静, 赵翠竹, 于逢春. 来适普治疗脑卒中后抑郁患者的疗效[J]. 心血管康复医学杂志, 2018, 27(4): 414-417.</mixed-citation></ref><ref id="hanspub.30513-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Siniscalchi, A., Iannacchero, R., Anticoli, S., et al. (2016) Anti-Inflammatory Strategies in Stroke: A Potential Therapeutic Target. Current Vascular Pharmacology, 14, 98-105. &lt;br&gt;https://doi.org/10.2174/1570161113666150923111329</mixed-citation></ref><ref id="hanspub.30513-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Cipriani, A., Purgato, M., Furukawa, T.A., et al. (2012) Citalopram versus Other Anti-Depressive Agents for Depression. Cochrane Database of Systematic Reviews, 7, CD006534. &lt;br&gt;https://doi.org/10.1002/14651858.CD006534.pub2</mixed-citation></ref><ref id="hanspub.30513-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Hackett, M.L., Anderson, C.S. and House, A.O. (2004) Interventions for Treating Depression after Stroke. Cochrane Database of Systematic Reviews. &lt;br&gt;https://doi.org/10.1002/14651858.CD003437.pub2</mixed-citation></ref><ref id="hanspub.30513-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Tu, J., Wang, L.X., Wen, H.F., Xu, Y.C. and Wang, P.F. (2018) The Association of Different Types of Cerebral Infarction with Post-Stroke Depression and Cognitive Impairment. Medicine, 97, e10919.  
&lt;br&gt;https://doi.org/10.1097/MD.0000000000010919</mixed-citation></ref><ref id="hanspub.30513-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Backhouse, E.V., McHutchison, C.A., Cvoro, V., Shenkin, S.D. and Wardlaw, J.M. (2018) Cognitive Ability, Education and Socioeconomic Status in Childhood and Risk of Post-Stroke Depression in Later Life: A Systematic Review and Meta-Analysis. PLoS ONE, 13, e0200525. &lt;br&gt;https://doi.org/10.1371/journal.pone.0200525</mixed-citation></ref><ref id="hanspub.30513-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Nabavi, S.F., Turner, A., Dean, O., et al. (2014) Post-Stroke Depression Therapy: Where Are We Now? Current Neurovascular Research, 11, 279-289. &lt;br&gt;https://doi.org/10.2174/1567202611666140522123504</mixed-citation></ref><ref id="hanspub.30513-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Loubinoux, I. and Chollet, F. (2010) Neuropharma-cology in Stroke Recovery. In: Cramer, S.C. and Nudo, R.J., Eds., Brain Repair after Stroke, Cambridge University Press, Cambridge, 183-193.  
&lt;br&gt;https://doi.org/10.1017/CBO9780511777547.018</mixed-citation></ref></ref-list></back></article>